Melanoma is the one of the most lethal form of cancer. It accounts for 75% of mortality related to skin cancer. Considerable progress in the treatment of metastatic melanoma has been made in recent years, with the approval of immune checkpoint inhibitors, cell-based therapies and other targeted approaches. Questions however still remain about the long-term efficacy of these agents and their potential side effects. There is an unmet need for the development of predictive imaging biomarkers of early tumour response to treatment. Our research focuses on the development of novel MRI/MRS, CT radiomics and SPECT imaging of Indium-111 radiolabelled immune cells to monitor and predict tumour response to treatment in patients. Zirconium-89 radiolabelling of cells and optical T-cell tracking methods are in preclinical development.
- L. Aloj*, B. Attili, D. Lau, C. Caraco, L. M. Lecherman, F. A. Gallagher et al. The emerging role of cell surface receptor and protein binding radiopharmaceuticals in cancer diagnostics and therapy. Nuclear Medicine and Biology 2020; S0969-8051(20)30149-9.
- L. M. Lechermann*, R Manavaki, T. Fryer, B. Attili, D. Lau, L. Jarvis, L. Aloj, B. Basu, F. Aigbirhio, M. Cleveland, N. Patel, F. Gallagher. Detection limit of Zirconium-89 labelled T-cells for cellular tracking: an in vitro approach using imaging on clinical PET/CT and PET/MRI. European Journal of Nuclear Medicine and Molecular Imaging Research 2020; 10:82.
- D. Lau*, F. Garçon, A. Chandra, L. M. Lechermann, L. Aloj, E. R. Chilvers, P. G. Corrie, K. Okkenhaug, F. A. Gallagher. Intravital imaging of adoptive T-cell morphology, mobility and trafficking following immune checkpoint inhibition in a mouse melanoma model. Frontiers in Immunology 2020; 11:1514.
- R. Rabbie*, N. Ansari-Pour, O. Cast, D Lau, F. Scott, F. A. Gallagher et al. Multi-site clonality analyses uncovers pervasive subclonal heterogeneity and branching evolution across melanoma metastases. Nature Communications 2020; 11:4306.